Cargando…

Severe Multi-Resistant Pemphigus vulgaris: prolonged remission with a single cycle of Rituximab

Pemphigus vulgaris is an autoimmune bullous disease whose therapy is based on systemic corticosteroids, with or without immunosuppressants. Rituximab is a chimeric monoclonal antibody of the IgG class, directed at a specific CD20 B cell surface antigen, used in pemphigus vulgaris empirically since 2...

Descripción completa

Detalles Bibliográficos
Autores principales: Corral, Isabela Soubhia, de Freitas, Thais Helena Proença, de Aquino, Renata Telles Rudge, Koller, Daniella Abbruzzini S., Magliari, Maria Elisa Ruffolo, Muller, Helena
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Sociedade Brasileira de Dermatologia 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3760947/
https://www.ncbi.nlm.nih.gov/pubmed/24068143
http://dx.doi.org/10.1590/abd1806-4841.20131990
_version_ 1782282828567805952
author Corral, Isabela Soubhia
de Freitas, Thais Helena Proença
de Aquino, Renata Telles Rudge
Koller, Daniella Abbruzzini S.
Magliari, Maria Elisa Ruffolo
Muller, Helena
author_facet Corral, Isabela Soubhia
de Freitas, Thais Helena Proença
de Aquino, Renata Telles Rudge
Koller, Daniella Abbruzzini S.
Magliari, Maria Elisa Ruffolo
Muller, Helena
author_sort Corral, Isabela Soubhia
collection PubMed
description Pemphigus vulgaris is an autoimmune bullous disease whose therapy is based on systemic corticosteroids, with or without immunosuppressants. Rituximab is a chimeric monoclonal antibody of the IgG class, directed at a specific CD20 B cell surface antigen, used in pemphigus vulgaris empirically since 2002, with success in 90% of the cases and long periods of remission. Male patient, 33 years old, diagnosed with pemphigus vulgaris, confirmed by histopathology and direct immunofluorescence. He was treated for seven months with numerous treatments, including immunosuppressive drugs, with an unsatisfactory response, until he had complete remission with the use of rituximab. During a 34-month follow-up period, the patient presented a slight clinical relapse, which was successfully controlled with prednisone in a daily dose of 120mg, soon reduced to 20mg.
format Online
Article
Text
id pubmed-3760947
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Sociedade Brasileira de Dermatologia
record_format MEDLINE/PubMed
spelling pubmed-37609472013-09-16 Severe Multi-Resistant Pemphigus vulgaris: prolonged remission with a single cycle of Rituximab Corral, Isabela Soubhia de Freitas, Thais Helena Proença de Aquino, Renata Telles Rudge Koller, Daniella Abbruzzini S. Magliari, Maria Elisa Ruffolo Muller, Helena An Bras Dermatol Case Report Pemphigus vulgaris is an autoimmune bullous disease whose therapy is based on systemic corticosteroids, with or without immunosuppressants. Rituximab is a chimeric monoclonal antibody of the IgG class, directed at a specific CD20 B cell surface antigen, used in pemphigus vulgaris empirically since 2002, with success in 90% of the cases and long periods of remission. Male patient, 33 years old, diagnosed with pemphigus vulgaris, confirmed by histopathology and direct immunofluorescence. He was treated for seven months with numerous treatments, including immunosuppressive drugs, with an unsatisfactory response, until he had complete remission with the use of rituximab. During a 34-month follow-up period, the patient presented a slight clinical relapse, which was successfully controlled with prednisone in a daily dose of 120mg, soon reduced to 20mg. Sociedade Brasileira de Dermatologia 2013 /pmc/articles/PMC3760947/ /pubmed/24068143 http://dx.doi.org/10.1590/abd1806-4841.20131990 Text en ©2013 by Anais Brasileiros de Dermatologia http://creativecommons.org/licenses/by-nc/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Report
Corral, Isabela Soubhia
de Freitas, Thais Helena Proença
de Aquino, Renata Telles Rudge
Koller, Daniella Abbruzzini S.
Magliari, Maria Elisa Ruffolo
Muller, Helena
Severe Multi-Resistant Pemphigus vulgaris: prolonged remission with a single cycle of Rituximab
title Severe Multi-Resistant Pemphigus vulgaris: prolonged remission with a single cycle of Rituximab
title_full Severe Multi-Resistant Pemphigus vulgaris: prolonged remission with a single cycle of Rituximab
title_fullStr Severe Multi-Resistant Pemphigus vulgaris: prolonged remission with a single cycle of Rituximab
title_full_unstemmed Severe Multi-Resistant Pemphigus vulgaris: prolonged remission with a single cycle of Rituximab
title_short Severe Multi-Resistant Pemphigus vulgaris: prolonged remission with a single cycle of Rituximab
title_sort severe multi-resistant pemphigus vulgaris: prolonged remission with a single cycle of rituximab
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3760947/
https://www.ncbi.nlm.nih.gov/pubmed/24068143
http://dx.doi.org/10.1590/abd1806-4841.20131990
work_keys_str_mv AT corralisabelasoubhia severemultiresistantpemphigusvulgarisprolongedremissionwithasinglecycleofrituximab
AT defreitasthaishelenaproenca severemultiresistantpemphigusvulgarisprolongedremissionwithasinglecycleofrituximab
AT deaquinorenatatellesrudge severemultiresistantpemphigusvulgarisprolongedremissionwithasinglecycleofrituximab
AT kollerdaniellaabbruzzinis severemultiresistantpemphigusvulgarisprolongedremissionwithasinglecycleofrituximab
AT magliarimariaelisaruffolo severemultiresistantpemphigusvulgarisprolongedremissionwithasinglecycleofrituximab
AT mullerhelena severemultiresistantpemphigusvulgarisprolongedremissionwithasinglecycleofrituximab